At Praedicare, we recognize that the emergence of antimicrobial resistance [AMR] to novel drugs is an integral part of the life cycle of that agent once approved for clinical use by drug regulating agencies, with dire global health consequences. Therefore, we developed a specific program to mitigate that, to predict that, and to diagnose that, even before drug gets to the clinic. We have developed a step-by-step approach, and the necessary standard operating procedures, to help biotech companies develop antimicrobials access this process. This includes antibacterial agents, antiviral agents, anti-parasitic agents, and antifungal agents. Out output includes optimal dosing strategies and identification of key companion drugs to mitigate Antimicrobial Resistance emergence, development of diagnostic kits to identify the resistance, and the solutions to apply when the resistance is eventually identified.